Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Clinical Trials
ALISCA™-Lung1 Active Sites
Puma anticipates opening the ALISCA™-Lung1 trial at approximately 25 study sites within the United States by the end of 2024. Below is a list of study sites currently open to enrollment as of 01OCT2024. Please note study site availability for enrollment is subject to change without notice. Please contact Puma at clinicaltrials@pumabiotechnology.com should you have any questions regarding open sites.
Center Name
City
State
Phone